From: Mixed response and time-to-event endpoints for multistage single-arm phase II design
Article | Treatment arms | Median TTP/PFS (Month) | Response rate (%) |
---|---|---|---|
Zhu et al., 2006 [22] | GEMOX + Bevacizumab | 5.3 | 20 |
Siegel et al., 2008 [23] | Bevacizumab | 6.9 | 13.04 |
Thomas et al., 2009 [24] | Bevacizumab + Erlotinib | 9.0 | 25 |
Hsu et al., 2010 [22] | Bevacizumab + Capecitabine | 2.7 | 8.89 |
Sun et al., 2011 [26] | Bevacizumab + Capecitabine + Oxaliplatin | 6.8 | 20 |
Kaseb et al., 2012 [27] | Bevacizumab + Erlotinib | 7.2 | 23.73 |
Philip et al., 2012 [28] | Bevacizumab + Erlotinib | 3.0 | 3.7 |
Yau et al., 2012 [29] | Bevacizumab + Erlotinib | 1.5 | 0 |